OBJECTIVES: To determine the clinical and pharmacoeconomic indicators from pharmacotherapeutic monitoring of patients using immunobiological (IMB) in a Health Insurance Company in Fortaleza - Brazil METHODS: Cross-sectional study in two hospitals accredited Insurance, from March/2012 to May 2013 (n = 96 patients). Data were recorded by medical (rheumatologist) in computerized management system (Sabius ®) performed after the query. Later, these were entered into Microsoft Excell 2007 and analyzed by clinical pharmacists auditors. The cost was calculated from the unit value in the book Brasíndice 765, using the Consumer Price Maximum and average weight of 70 kg in standard doses. RESULTS: Most patients were women (66, 68.75%), averaging 67 kg, aged between 30-59 years (62.50%) and higher incidence of rheumatoid arthritis among the diseases treated (45; 46.88%). The higher costs per capita were checked with Infliximab (R$ 62,459.40) and abatacept (R$ 41,989.55), while Adalimumab (R$ 16,614.60) and golimumab (R$ 10,385.05) represented the lowest cost per capita. There was a significant difference between the average cost per capita of IMB intravenous (91, R$ 48,975.27) and subcutaneous (11, R$ 10,695.49). The average cost for treatment / dose first line was R$ 6,068.91 and the second line was R $ 9,590.06, resulting in an incremental cost / dose of R $ 3,521.16 (36.72%). CONCLUSIONS: The pharmacotherapeutic monitoring becomes important for planning strategies aimed at streamlining and optimization of these drugs and pharmacoeconomic clinical management.